Artificial Intelligence Meets Vascular Health: Identifying Molecules for Precision Repair of Barrier Dysfunctions

Abstract

Vascular barrier dysfunctions pose significant health risks, contributing to pathological conditions characterized by increased permeability and inflammation. This study explores the potential of artificial intelligence (AI) in identifying small molecules that can effectively target and repair these dysfunctions. The fundamental mechanisms underlying vascular barrier integrity, common causes of dysfunction, and the role of small molecules in therapeutic repair are discussed. Existing research gaps and limitations of traditional drug discovery approaches necessitating innovative solutions are highlighted. Integrating AI techniques such as machine learning, molecular docking, and virtual screening represents a paradigm shift in drug discovery, offering enhanced efficiency and accuracy in identifying promising candidates. Successful case studies demonstrate the effectiveness of AI-driven methodologies, while challenges related to data limitations and biological validation are also addressed. Looking ahead, the collaboration between AI and multi-omics approaches is poised to transform vascular medicine, facilitating personalized therapeutic strategies and ultimately improving patient outcomes.

References

1. Sturtzel, C. Endothelial cells. Immunol. Cardiovasc. Homeost. Pathol. 2017, 71–91.
2. Di Tommaso, N.; Gasbarrini, A.; Ponziani, F.R. Intestinal barrier in human health and disease. Int. J. Environ. Res. Public Health 2021, 18(23), 12836.
3. Chen, L.; Deng, H.; Cui, H.; Fang, J.; Zuo, Z.; Deng, J.; ... Zhao, L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2018, 9(6), 7204.
4. Schoultz, I.; Keita, Å.V. Cellular and molecular therapeutic targets in inflammatory bowel disease—focusing on intestinal barrier function. Cells 2019, 8(2), 193.
5. Guo, X.; Liu, R.; Jia, M.; Wang, Q.; Wu, J. Ischemia-reperfusion injury induced blood-brain barrier dysfunction and the involved molecular mechanism. Neurochem. Res. 2023, 48(8), 2320–2334.
6. He, P.; Talukder, M.H.; Gao, F. Oxidative stress and microvessel barrier dysfunction. Front. Physiol. 2020, 11, 472.
7. Leyane, T.S.; Jere, S.W.; Houreld, N.N. Oxidative stress in aging and chronic degenerative pathologies: molecular mechanisms involved in counteracting oxidative stress and chronic inflammation. Int. J. Mol. Sci. 2022, 23(13), 7273.
8. Incalza, M.A.; D'Oria, R.; Natalicchio, A.; Perrini, S.; Laviola, L.; Giorgino, F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vasc. Pharmacol. 2018, 100, 1–19.
9. Józefczuk, E.; Guzik, T.J.; Siedlinski, M. Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacol. Res. 2020, 156, 104793.
10. Cepaityte, D.; Leivaditis, K.; Varouktsi, G.; Roumeliotis, A.; Roumeliotis, S.; Liakopoulos, V. N-Acetylcysteine: more than preventing contrast-induced nephropathy in uremic patients—focus on the antioxidant and anti-inflammatory properties. Int. Urol. Nephrol. 2023, 55(6), 1481–1492.
11. Nong, J.; Glassman, P.M.; Muzykantov, V.R. Targeting vascular inflammation through emerging methods and drug carriers. Adv. Drug Deliv. Rev. 2022, 184, 114180.
12. Fountzilas, E.; Tsimberidou, A.M.; Vo, H.H.; Kurzrock, R. Clinical trial design in the era of precision medicine. Genome Med. 2022, 14(1), 101.
13. Ahmed, A.S.I.; Blood, A.B.; Zhang, L. Hypoxia-induced pulmonary hypertension in adults and newborns: implications for drug development. Drug Discov. Today 2024, 104015.
14. Nagarajan, K.; Sundaram, D.P.; Marimuthu, S.K. Innovations in Pharmaceutical Biotechnology. Acad. Guru Publ. House 2024.
15. De Stefano, P.; Bianchi, E.; Dubini, G. The impact of microfluidics in high-throughput drug-screening applications. Biomicrofluidics 2022, 16(3).
16. Anand, U.; Dey, A.; Chandel, A.K.S.; Sanyal, R.; Mishra, A.; Pandey, D.K.; ... de la Lastra, J.M.P. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023, 10(4), 1367–1401.
17. Chi, L.H.; Burrows, A.D.; Anderson, R.L. Can preclinical drug development help to predict adverse events in clinical trials? Drug Discov. Today 2022, 27(1), 257–268.
18. Gangwal, A.; Ansari, A.; Ahmad, I.; Azad, A.K.; Sulaiman, W.M.A.W. Current strategies to address data scarcity in artificial intelligence-based drug discovery: a comprehensive review. Comput. Biol. Med. 2024, 179, 108734.
19. Huang, E.T.; Yang, J.S.; Liao, K.Y.; Tseng, W.C.; Lee, C.K.; Gill, M.; ... Tsai, F.J. Predicting blood-brain barrier permeability of molecules with a large language model and machine learning. Sci. Rep. 2024, 14(1), 15844.
20. Singh, S.; Gupta, H.; Sharma, P.; Sahi, S. Advances in Artificial Intelligence (AI)-assisted approaches in drug screening. Artif. Intell. Chem. 2024, 2(1), 100039.
21. Scioli, M.G.; Storti, G.; D’Amico, F.; Rodríguez Guzmán, R.; Centofanti, F.; Doldo, E.; Orlandi, A. Oxidative stress and new pathogenetic mechanisms in endothelial dysfunction: potential diagnostic biomarkers and therapeutic targets. J. Clin. Med. 2020, 9 (6), 1995.
22. Raparthi, M.; Gayam, S.R.; Nimmagadda, V.S.P.; Sahu, M.K.; Putha, S.; Pattyam, S.P.; Kuna, S.S. AI-assisted drug discovery: Emphasizing its role in accelerating precision medicine initiatives and improving treatment outcomes. Hum.-Comput. Interact. Perspect. 2022, 2 (2), 1–10.
23. Saheed, Y.K.; Salau-Ibrahim, T.T.; Abdulsalam, M.; Adeniji, I.A.; Balogun, B.F. Modified bi-directional long short-term memory and hyperparameter tuning of supervised machine learning models for cardiovascular heart disease prediction in the mobile cloud environment. Biomed. Signal Process. Control 2024, 94, 106319.
24. Razzaq, M.; Aslam, M.; Aqeel, M.B.; Malik, M.; Haroon, R.; Kalsoom, U. The Role of Artificial Intelligence in Predicting Cardiovascular Diseases: Current Trends and Future Directions. Azerb. Pharm. Pharmacother. J. 2024, 23, 1–19.
25. AR, N.; GK, R. A deep learning and docking simulation-based virtual screening strategy enables the rapid identification of HIF-1α pathway activators from a marine natural product database. J. Biomol. Struct. Dyn. 2024, 42 (2), 629–651.
26. Gholap, A.D.; Uddin, M.J.; Faiyazuddin, M.; Omri, A.; Gowri, S.; Khalid, M. Advances in Artificial Intelligence in Drug Delivery and Development: A Comprehensive Review. Comput. Biol. Med. 2024, 108702.
27. Duo, L.; Liu, Y.; Ren, J.; Tang, B.; Hirst, J.D. Artificial intelligence for small molecule anticancer drug discovery. Expert Opin. Drug Discov. 2024, 1–16.
28. Du, C.; Zhuang, J.; Huang, X. Deep learning technology in vascular image segmentation and disease diagnosis. J. Intell. Med. 2024.
29. Kırboğa, K.K.; Abbasi, S.; Küçüksille, E.U. Explainability and white box in drug discovery. Chem. Biol. Drug Des. 2023, 102 (1), 217–233.
30. Khera, R.; Oikonomou, E.K.; Nadkarni, G.N.; Morley, J.R.; Wiens, J.; Butte, A.J.; Topol, E.J. Transforming cardiovascular care with artificial intelligence: from discovery to practice: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2024, 84 (1), 97–114.
31. Dickson, M.; Gagnon, J.P. The cost of new drug discovery and development. Discov. Med. 2009, 4 (22), 172–179.
32. Dhudum, R.; Ganeshpurkar, A.; Pawar, A. Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications. Drugs Drug Candidates 2024, 3 (1), 148–171.
33. Deng, J.; Yang, Z.; Ojima, I.; Samaras, D.; Wang, F. Artificial intelligence in drug discovery: applications and techniques. Brief. Bioinform. 2022, 23 (1), 430.
34. Abdulsalam, M.; Fatima, Z.Y.U.; Hasiya, U.A.; Ummulkhuthum, A.T.; Aisha, W.N.; Muhammad, F.Y. Deciphering the Genetic Code: Mechanisms, Evolution, and Implications for Biotechnology. World J. Adv. Res. Rev. 2024, 21 (1), 858–868.
35. Abdulsalam, M.; Ila, M.A. Closing the Gap: Artificial Intelligence Integration for Advancing Chikungunya Virus Studies in Africa. Biol. Sci. 2023, 3 (4), 493–502.
36. Abdulsalam, M.; Amina, A.A.; Ummulkhair, A.Y.; Zainab, H.F. Advances in understanding the interplay between Mutagenesis and DNA repair: Implications for Genomic Stability and Evolution. Int. J. Sci. Acad. Res. 2023, 4 (10), 6428–6438.
37. Staszak, M.; Staszak, K.; Wieszczycka, K.; Bajek, A.; Roszkowski, K.; Tylkowski, B. Machine learning in drug design: Use of artificial intelligence to explore the chemical structure–biological activity relationship. Wiley Interdiscip. Rev. Comput. Mol. Sci. 2022, 12 (2), e1568.
38. Saheed, Y.K.; Balogun, B.F.; Odunayo, B.J.; Abdulsalam, M. Microarray gene expression data classification via Wilcoxon sign rank sum and novel Grey Wolf optimized ensemble learning models. IEEE/ACM Trans. Comput. Biol. Bioinform. 2023, 20 (6), 3575–3587.
39. Lavecchia, A.; Di Giovanni, C. Virtual screening strategies in drug discovery: a critical review. Curr. Med. Chem. 2013, 20 (23), 2839–2860.
40. Vázquez, J.; López, M.; Gibert, E.; Herrero, E.; Luque, F.J. Merging ligand-based and structure-based methods in drug discovery: An overview of combined virtual screening approaches. Molecules 2020, 25 (20), 4723.
41. Sandoval, P.J.; Santiago, J. In vitro analytical approaches to study plant ligand-receptor interactions. Plant Physiol. 2020, 182 (4), 1697–1712.
42. Dara, S.; Dhamercherla, S.; Jadav, S.S.; Babu, C.M.; Ahsan, M.J. Machine learning in drug discovery: a review. Artif. Intell. Rev. 2022, 55 (3), 1947–1999.
43. Pasrija, P.; Jha, P.; Upadhyaya, P.; Khan, M.S.; Chopra, M. Machine learning and artificial intelligence: a paradigm shift in big data-driven drug design and discovery. Curr. Top. Med. Chem. 2022, 22 (20), 1692–1727.
44. Abdulsalam, M.; Hamisu, A.A.; Ahmad, A.M.; Wakili, F.B.; Annu, F.S.; Garba, M.M. Microbiome Dynamics and Strategic Management Strategies: Exploring Synergies between Integrative Medicine Modalities and Microbial Balance. Biol. Sci. 2024, 4 (3), 725–735.
45. Srivastava, N.; Verma, S.; Singh, A.; Shukla, P.; Singh, Y.; Oza, A.D.; Yadav, A.N. Advances in artificial intelligence-based technologies for increasing the quality of medical products. DARU J. Pharm. Sci. 2025, 33 (1), 1–21.
46. You, Y.; Lai, X.; Pan, Y.; Zheng, H.; Vera, J.; Liu, S.; Zhang, L. Artificial intelligence in cancer target identification and drug discovery. Signal Transduct. Target. Ther. 2022, 7 (1), 156.
47. Stawicki, S.P.; Jeanmonod, R.; Miller, A.C.; Paladino, L.; Gaieski, D.F.; Yaffee, A.Q.; Garg, M. The 2019–2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint American College of Academic International Medicine-world Academic Council of Emergency Medicine multidisciplinary COVID-19 working Group consensus paper. J. Glob. Infect. Dis. 2020, 12 (2), 47–93.
48. Duong, C.N.; Vestweber, D. Mechanisms ensuring endothelial junction integrity beyond VE-cadherin. Front. Physiol. 2020, 11, 519.
49. . Abdulsalam M., Innocent M.O., Livinus M.U., Abdulhakeem A.I., Danjuma F.A., Khadijah A., Tajudeen T.A., Lateefat A.A., Temitope I.A., Adekunle I.J. Community health and vulnerability. In: The interplay of pesticides and climate change: environmental dynamics and challenges. Cham: Springer Nature Switzerland; 2025. p. 443–467.
50. Shao, Y.; Cheng, Z.; Li, X.; Chernaya, V.; Wang, H.; Yang, X.F. Immunosuppressive/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction-a novel mechanism for maintaining vascular function. J. Hematol. Oncol. 2014, 7, 1–14.
51. Neuvians, T.P.; Berisha, B.; Schams, D. Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) expression during induced luteolysis in the bovine corpus luteum. Mol. Reprod. Dev. 2004, 67 (4), 389–395.
52. Raeeszadeh-Sarmazdeh, M.; Do, L.D.; Hritz, B.G. Metalloproteinases and their inhibitors: potential for the development of new therapeutics. Cells 2020, 9 (5), 1313.
53. Wu, X.; Zhang, Q.; Guo, Y.; Zhang, H.; Guo, X.; You, Q.; Wang, L. Methods for the Discovery and Identification of small molecules targeting oxidative stress-related protein-protein interactions: An Update. Antioxidants 2022, 11 (4), 619.
54. Sinha, A.; Roy, S. Prospective therapeutic targets and recent advancements in the treatment of inflammatory bowel disease. Immunopharmacol. Immunotoxicol. 2024, 46 (4), 550–563.
55. Van Norman, G.A. Limitations of animal studies for predicting toxicity in clinical trials: Part 2: Potential alternatives to the use of animals in preclinical trials. Basic Transl. Sci. 2020, 5 (4), 387–397.
56. Eloy, J.O.; de Souza, M.C.; Petrilli, R.; Barcellos, J.P.A.; Lee, R.J.; Marchetti, J.M. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf. B Biointerfaces 2014, 123, 345–363.
57. Gude, S.; Gude, Y.S. The synergy of artificial intelligence and machine learning in revolutionizing pharmaceutical regulatory affairs. Transl. Regul. Sci. 2024, 6 (2), 37–45.
58. Sverdlov, O.; Van Dam, J.; Hannesdottir, K.; Thornton-Wells, T. Digital therapeutics: an integral component of digital innovation in drug development. Clin. Pharmacol. Ther. 2018, 104 (1), 72–80.
59. Mak, K.K.; Wong, Y.H.; Pichika, M.R. Artificial intelligence in drug discovery and development. Drug Discov. Eval. Saf. Pharmacokinet. Assays 2024, 1461–1498.
60. Abdulsalam, M. Exploring the Therapeutic Promise of Cationic Antibacterial Peptides. Biol. Sci. 2024, 4 (3), 692–700.
61. Vogt, M. Using deep neural networks to explore chemical space. Expert Opin. Drug Discov. 2022, 17 (3), 297–304.
62. Yu, Y.; Chen, Y.; Huang, S.; Wang, R.; Wu, Y.; Zhou, H.; Tan, Z. Enhancing the effluent prediction accuracy with insufficient data based on transfer learning and LSTM algorithm in WWTPs. J. Water Process Eng. 2024, 62, 105267.
63. Evans, R.P.; Bryant, L.D.; Russell, G.; Absolom, K. Trust and acceptability of data-driven clinical recommendations in everyday practice: A scoping review. Int. J. Med. Inform. 2024, 105342.
64. Bugrim, A.; Nikolskaya, T.; Nikolsky, Y. Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov. Today 2004, 9 (3), 127–135.
65. Gervasini, G.; Benítez, J.; Carrillo, J.A. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur. J. Clin. Pharmacol. 2010, 66, 755–774.
66. Askin, S.; Burkhalter, D.; Calado, G.; El Dakrouni, S. Artificial intelligence applied to clinical trials: opportunities and challenges. Health Technol. 2023, 13 (2), 203–213.
67. Musa, I.O.; Isibor, P.O.; Samuel, J.O.; Mustapha, A.; Mustapha, A.; Akande, S.; Adeniji, H. Introduction to Nanotoxicology. In Environmental Nanotoxicology: Combatting the Minute Contaminants; Springer Nature Switzerland: Cham, 2024; pp. 1–22.
68. Esmaeilzadeh, P.; Mirzaei, T.; Dharanikota, S. Patients’ perceptions toward human–artificial intelligence interaction in health care: experimental study. J. Med. Internet Res. 2021, 23 (11), e25856.
69. Saheed Y.K., Abdulganiyu O.H., Abdulsalam M., Mustapha M., Olivier M.M., Majikumna K.U. A hybrid ant colony optimization for Parkinson’s disease classification based on synthetic minority oversampling and adaptive synthetic techniques. In: 2024 5th International Conference on Data Analytics for Business and Industry (ICDABI); 2024. p. 16–23.
70. Ahmed A.A., Yusuf U.A., Fadlallah Z.H., Innocent M.O., Abdulsalam M. Developing an omics-driven computational framework for next-generation microbiome therapeutics. Biol Sci. 2024;19(4):810–821
71. Abdulsalam, M.; Musa, I.O.; Livinus, M.U.; Elelu, S.A.; Ibrahim, G.O.; Salami, O.L.; Pal, S.K. Blue Bioeconomy and Biomedical Innovation. In Marine Bioprospecting for Sustainable Blue-bioeconomy; Springer Nature Switzerland: Cham, 2024; pp. 143–157.
72. Mennella, C.; Maniscalco, U.; De Pietro, G.; Esposito, M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. Heliyon 2024.
73. Dou, B.; Zhu, Z.; Merkurjev, E.; Ke, L.; Chen, L.; Jiang, J.; Wei, G.W. Machine learning methods for small data challenges in molecular science. Chem. Rev. 2023, 123 (13), 8736–8780.
74. Abdulsalam, M.; Hamisu, A.A.; Ahmad, A.M.; Wakili, F.B.; Rabiu, I.B.; Burodo, R.A.; Iliyas, N.A. Synergies at the Intersection: Exploring the Role of Bioinformatics in Enhancing Physiotherapy and Nursing Practice. Biol. Sci. 2024, 4 (3), 712–724.
75. Zhao, K.; Zeng, Z.; He, Y.; Zhao, R.; Niu, J.; Sun, H.; Zhou, J. Recent advances in targeted therapy for inflammatory vascular diseases. J. Controlled Release 2024, 372, 730–750.
76. Benavides-Hernández, J.; Dumeignil, F. From Characterization to Discovery: Artificial Intelligence, Machine Learning and High-Throughput Experiments for Heterogeneous Catalyst Design. ACS Catal. 2024, 14 (15), 11749–11779.
77. Dinh-Le, C.; Chuang, R.; Chokshi, S.; Mann, D. Wearable health technology and electronic health record integration: a scoping review and future directions. JMIR mHealth uHealth 2019, 7 (9), e12861.
78. Kalinin, A.A.; Higgins, G.A.; Reamaroon, N.; Soroushmehr, S.; Allyn-Feuer, A.; Dinov, I.D.; Athey, B.D. Deep learning in pharmacogenomics: from gene regulation to patient stratification. Pharmacogenomics 2018, 19 (7), 629–650.
79. Zeb, S.; Nizamullah, F.N.U.; Abbasi, N.; Fahad, M. AI in Healthcare: Revolutionizing Diagnosis and Therapy. Int. J. Multidiscip. Sci. Arts 2024, 3 (3), 118–128.
80. Huang, J.D.; Wang, J.; Ramsey, E.; Leavey, G.; Chico, T.J.; Condell, J. Applying artificial intelligence to wearable sensor data to diagnose and predict cardiovascular disease: a Review. Sensors 2022, 22 (20), 8002.
81. Biswas, N.; Chakrabarti, S. Artificial intelligence (AI)-based systems biology approaches in multi-omics data analysis of cancer. Front. Oncol. 2020, 10, 588221.
82. Ullah, M.; Hamayun, S.; Wahab, A.; Khan, S.U.; Rehman, M.U.; Haq, Z.U.; Naeem, M. Smart technologies are used as smart tools in the management of cardiovascular disease and their future perspective. Curr. Probl. Cardiol. 2023, 48 (11), 101922.
83. Li, J.; Zheng, M.; Shimoni, O.; Banks, W.A.; Bush, A.I.; Gamble, J.R.; Shi, B. Development of novel therapeutics targeting the blood-brain barrier: from barrier to carrier. Adv. Sci. 2021, 8 (16), 2101090.
84. Hoque, M.N.; Sarkar, M.M.H.; Khan, M.A.; Hossain, M.A.; Hasan, M.I.; Rahman, M.H.; Islam, T. Differential gene expression profiling reveals potential biomarkers and pharmacological compounds against SARS-CoV-2: Insights from machine learning and bioinformatics approaches. Front. Immunol. 2022, 13, 918692.
85. Chakraborty, S.; Sharma, G.; Karmakar, S.; Banerjee, S. Multi-OMICS approaches in cancer biology: New era in cancer therapy. Biochim. Biophys. Acta Mol. Basis Dis. 2024, 1870 (5), 167120.
86. Abdulsalam, M.; Salihu, A.T.; Usman, H.Y.; Usman, M.Y. Protein Biosynthesis in Microorganisms: Mechanisms, Regulation, and Biotechnological Applications. World J. Adv. Res. Rev. 2024, 21 (1), 869–881.
87. Yang, C.; Zhang, H.; Zhang, L.; Zhu, A.X.; Bernards, R.; Qin, W.; Wang, C. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2023, 20 (4), 203–222.